Future of drugs-Diabetes_Luseogliflozin
Drug Name Luseogliflozin Structure Drug Code TS-071 Synonym (2S,3R,4R,5S,6R)-2-[5-(4-Ethoxybenzyl)-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol Molecular Formula C 23 H 30 O 6 S Innovator Taisho Toyama Pharmaceutical Novartis for marketing Condition Type-2 diabetes mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase I Approval Approved in Japan in March 2014.